MiR-210 links hypoxia with cell proliferation regulation in human laryngocarcinoma cancer

Journal of Cellular Biochemistry

Volumn 116, Issue 6, 2015, Pages 1039-1049

  Zuo, Jianhong ^a,b   Wen, Meiling ^b   Lei, Mingsheng ^c   Peng, Xiang ^d   Yang, Xuefeng ^b   Liu, Zhigang ^a  

^a Shenzhen University School of Medicine   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

^c Department of Ophthalmology   (China)

^d SHENZHEN UNIVERSITY   (China)

Author keywords

CELL PROLIFERATION; FGFRL1; HYPOXIA; LARYNGOCARCINOMA CANCER; MiR 210

Indexed keywords

CASPASE 3; CASPASE 7; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA 210; MICRORNA; MIRN210 MICRORNA, HUMAN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL HYPOXIA; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HEK293 CELL LINE; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LARYNX CARCINOMA; LASER CAPTURE MICRODISSECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; IMMUNOHISTOCHEMISTRY; METABOLISM; NUDE MOUSE; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84925857842     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.25059     Document Type: Article

References (40)

1. Ambros V,. 2008. The evolution of our thinking about microRNAs. Nat Med 14: 1036-1040.
2. American Cancer Society Ed., Cancer Facts, and Figures (2012) American Cancer Society, Atlanta, GA, USA 2012.
3. Bədulescu F, Bədulescu A, Crişan A, Popescu FC,. 2013. Study of the diagnosis and treatment of cancer located in the head and neck and correlation with expression of prognostic markers. Rom J Morphol Embryol 54: 487-497.
4. Ballo H, Koldovsky P, Hoffmann T, Balz V, Hildebrandt B, Gerharz CD, Bier H,. 1999. Establishment and characterization of four cell lines derived from human head and neck squamous cell carcinomas for an autologous tumorfibroblast in vitro model. Anticancer Res 19: 3827-3836.
5. Bindra R, Crosby M, Glazer P,. 2007. Regulationof DNA repair in hypoxic cancer cells. Cancer Metastasis Rev 26: 249-260.
6. Boeckx C, Weyn C, Vanden-Bempt I, Deschoolmeester V, Wouters A, Specenier P, Van Laer C, Van den Weyngaert D, Kockx M, Vermorken JB, Peeters M, Pauwels P, Lardon F, Baay M,. 2014. Mutation analysis of genes in the EGFR pathway in head and neck cancer patients: implications for anti-EGFR treatment response. BMC Res Notes 7: 337. DOI: 10.1186/1756-0500-7-337
7. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM, Ragoussis J,. 2008. Hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 14: 1340-1348.
8. Chan SY, Zhang YY, Hemann C, Mahoney CE, Zweier JL, Loscalzo J,. 2009. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab 10: 273-284.
9. Cheng AL, Huang WG, Chen ZC, Peng F, Zhang PF, Li MY, Li F, Li JL, Li C, Yi H, Yi B, Xiao ZQ,. 2008. Identification of novel nasopharyngeal carcinoma biomarkers by laser capture microdissection and proteomic analysis. Clin Cancer Res 14 (2): 435-445.
10. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM,. 2009. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res 69: 1221-1229.
11. Jordanovski D, Herwartz C, Pawlowski A, Taute S, Frommolt P, Steger G,. 2013. The Hypoxia-inducible transcription factor ZNF395 is controlled by IkB kinase-signaling and activates genes involved in the innate immune response and cancer. Plos ONE 8: e74911.
12. Fasanaro P, D'Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pompilio G, Capogrossi MC, Martelli F,. 2008. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand ephrin-A3. J Biol Chem 283: 15878-15883.
13. Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, Betts G, Homer J, Corbridge R, Cox G, West CM, Ragoussis J, Harris AL,. 2010. Hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer 116: 2148-2158.
14. Goda N, Dozier SJ, Johnson RS,. 2003. HIF-1 in cell cycle regulation, apoptosis, and tumor progression. Antioxid Redox Signal 5 (4): 467-473.
15. Giannakakis A, Sandaltzopoulos R, Greshock J, Liang S, Huang J, Hasegawa K, Li C, O'Brien-Jenkins A, Katsaros D, Weber BL, Simon C, Coukos G, Zhang L,. 2008. MiR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 7: 255-264.
16. Hanahan D, Weinberg RA,. 2011. Hallmarks of cancer: the next generation. Cell 144 (5): 646-674.
17. Harris AL,. 2010. Hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer. 116: 2148-2158.
18. He J, Wu J, Xu N, Xie W, Li M, Li J, Jiang Y, Yang BB, Zhang Y,. 2013. MiR-210 disturbs mitotic progression through regulating a group of mitosis-related genes. Nucleic Acids Res 41: 498-508.
19. Hong L, Yang J, Han Y, Lu Q, Cao J, Syed L,. 2012. High expression of miR-210 predicts poor survival in patients with breast cancer: A meta-analysis. Gene 507: 135-138.
20. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT, Giaccia AJ,. 2009. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 35: 856-867.
21. Jiang LY, Lian M, Wang H, Fang JG, Wang Q,. 2012. Inhibitory effects of 5-Aza-2'- deoxy- cytidine and trichostatin A in combination with p53-expressing adenovirus on human laryngocarcinoma cells. Chin J Cancer Res 24: 232-237.
22. Kikuchi M, Yamane T, Shinohara S, Fujiwara K, Hori SY, Tona Y, Yamazaki H, Naito Y, Senda M,. 2011. 18F-fluoromisonidazole positron emission tomography before treatment isapredictorof radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Ann Nucl Med 25 (9): 625-633.
23. Kim HW, Haider HK, Jiang S, Ashraf M,. 2009. Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem 284: 33161-33168.
24. Kosaka N, Iguchi H, Hagiwara K, Yoshioka Y, Takeshita F, Ochiya T,. 2013. Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis. J Biol Chem 288 (15): 10849-10859.
25. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD,. 2002. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1 (3): 247-255.
26. Masuda M, Toh S, Wakasaki T, Suzui M, Joe AK,. 2013. Somatic evolution of head and neck cancer-biological robustness and latent vulnerability. Mol Oncol 1: 14-28.
27. Mutharasan RK, Nagpal V, Ichikawa Y, Ardehali H,. 2011. MicroRNA-210 is upregulated in hypoxic cardiomyocytes through Akt- and p53-dependent pathways and exerts cytoprotective effects. Am J Physiol Heart Circ Physiol 301: H1519-H1530.
28. Nie Y, Han BM, Liu XB, Yang JJ, Wang F, Cong XF, Chen X,. 2011. Identification Of microRNAs involved in hypoxia-and serum deprivation-induced apoptosis in mesenchymal stem cells. Int J Biol Sci 7: 762-768.
29. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TLJ, Visakorpi T,. 2007. MicroRNA expression profiling in prostate cancer. Cancer Res 67: 6130-6135.
30. Pulte D, Brenner H,. 2010. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 15: 994-1001.
31. Rajendran J, Schwartz D, O'Sullivan J, Peterson LM, Ng P, Scharnhorst J, Grierson JR, Krohn KA,. 2006. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 12: 5435-5341.
32. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ,. 2005. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25 (13): 5675-5686.
33. Rothe F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, Badran B, Fayyad-Kazan H, Desmedt C, Harris AL, Piccart M, Sotiriou C,. 2011. Global microRNA expression profiling identifies miR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS ONE 6: e20980.
34. Shen GM, Li XB, Jia YF, Piazza GA, Xi Y,. 2013. Hypoxia-regulated microRNAs in human cancer. Acta Pharmacologica Sinica 34: 336-341.
35. Wang J, Zhao J, Shi M, Ding Y, Sun H, Yuan F, Zou Z,. 2014. Elevated expression of miR-210 predicts poor survival of cancer patients: A systematic review and meta- analysis. PLoS ONE 9 (2): e89223.
36. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI, Dang CV, Semenza GL,. 2007. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11: 407-420.
37. Zhang Z, Sun H, Dai H, Walsh RM, Imakura M, Schelter J, Burchard J, Dai X, Chang AN, Diaz RL, Marszalek JR, Bartz SR, Carleton M, Cleary MA, Linsley PS, Grandori C,. 2009. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 8: 1-13.
38. Zhang M, Truscott J, Davie J,. 2013. Loss of MEF2D expression inhibits differentiation and contributes to oncogenesis in rhabdomyosarcoma cells. Mol Cancer 12 (150): 1-14.
39. Zuo J, Ishikawa T, Boutros S, Xiao Z, Humtsoe JO, Kramer RH,. 2010. Bcl-2 overexpression induces a partial epithelial to mesenchymal transition and promotes squamous carcinoma cell invasion and metastasis. Mol Cancer Res 8: 170-182.
40. Zuo J, Zhu W, Li MY, Li XH, Yi H, Zeng GQ, Wan XX, He QY, Li JH, Qu JQ, Xiao ZQ,. 2011. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. J Cell Biochem 112: 2508-2517.